Jun 19, 2020
Notice
Kringle Pharma announces that positive clinical results from Phase I/II trial of recombinant human HGF, KP-100IT, in subjects with acute spinal cord injury were published in the peer-reviewed Journal of Neurotrauma (Published Online: 22 May 2020, DOI: 10.1089/neu.2019.6854).
Kringle Pharma announces that positive clinical results from Phase I/II trial of recombinant human HGF, KP-100IT, in subjects with acute spinal cord injury were published in the peer-reviewed Journal of Neurotrauma (Published Online: 22 May 2020, DOI: 10.1089/neu.2019.6854).